China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for a radioactive in vivo diagnostic drug. The drug is intended for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer patients.
Drug Profile
The Category 1 chemical drug targets PSMA and is not yet commercially available anywhere. It is suitable for prostate cancer patients who are about to receive initial radical treatment and are suspected of having metastases, as well as those with elevated serum prostate-specific antigen (PSA) levels suspected of biochemical recurrence.-Fineline Info & Tech
